New Drugs or Established Regimens for the Management of Type 2 Diabetes – Are the Choices and Decisions Facing Consultants and Their Patients Straightforward?
Brown Beata, IG Holt Richard
For decades only insulin, sulphonylureas and metformin were available, but in the last 10 years new classes of drugs have been approved for diabetes management. These include alpha glucosidase inhibitors, thiazolidinediones, glinides, incretin-based treatments such as glucagonlike peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors. Insulin analogues have been developed, enabling easier and more physiological […]